CAHIC(SH:600195) China Post Securities·2025-09-02 11:07Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [7][10]. Core Insights - The company reported a revenue of 2.793 billion yuan for the first half of 2025, representing a year-on-year growth of 12.63%, with a net profit attributable to shareholders of 82 million yuan, up 30.19% year-on-year [5]. - The animal vaccine business continues to face pressure, while the pharmaceutical and feed segments have shown significant revenue growth [5][6]. - The pharmaceutical segment achieved nearly 1 billion yuan in revenue, a substantial increase of 57.36% year-on-year, with improved gross margins [6]. - The feed segment also saw a notable revenue increase of 23.54%, reaching 536 million yuan [6]. Financial Performance Summary - The company’s total revenue is projected to grow from 6.017 billion yuan in 2024 to 7.896 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 11.55% [8][9]. - The net profit attributable to shareholders is expected to rise from 708.8 million yuan in 2024 to 3589.8 million yuan in 2027, reflecting a significant recovery and growth trajectory [8][9]. - Earnings per share (EPS) are forecasted to increase from 0.07 yuan in 2024 to 0.35 yuan in 2027, indicating strong profitability growth [8][9].